Monoclonal antibodies constitute a promising class of targeted anticancer agents that
enhance natural immune system functions to suppress cancer cell activity and eliminate …

Cancer immunotherapy has been firmly established as a new milestone for cancer therapy,
with the development of multiple immune cells as therapeutic tools. Natural killer (NK) cells …

Natural killer (NK) cells can induce an antigen-independent immune response against
malignant cells. A growing number of scientific reports and clinical studies have shown …

We developed cergutuzumab amunaleukin (CEA-IL2v, RG7813), a novel monomeric CEA-
targeted immunocytokine, that comprises a single IL-2 variant (IL2v) moiety with abolished …

Natural killer (NK) cells are attractive within adoptive transfer settings in cancer
immunotherapy due to their potential for allogeneic use; their alloreactivity is enhanced …

Despite advances in the diagnostic and therapeutic modalities, the prognosis of several
solid tumor malignancies remains poor. Different factors associated with solid tumors …

The activating receptor natural killer group 2, member D (NKG2D) is involved in both innate
and adaptive immunities, and functions as a “master switch” in determining the activation …

Cytokines regulate both the innate and adaptive immune responses to cancer. Although
antitumor activity has been seen for several cytokines in preclinical models, they have had …

Antibody-cytokine fusion proteins (immunocytokine) exert a potent anti-cancer effect; indeed,
they target the immunosuppressive tumor microenvironment (TME) due to a specific anti …

Nature killer (NK) cells play a critical role in host innate and adaptive immune defense
against viral infections and tumors. NK cells are enriched in liver hematopoietic cells with …